Mitchell von Itzstein, M.D.

Internal Medicine - Hematology/Oncology
Lung Cancer
Immunotherapy

New Patient Appointment Accepting Virtual Visits or 214-645-4673

Biography

Mitchell von Itzstein, M.D., is an Assistant Professor in the Department of Internal Medicine’s Division of Hematology and Oncology at UT Southwestern Medical Center. He specializes in lung cancer, thoracic oncology, and cancer immunotherapy. His clinical interests include the treatment of lung cancer and other thoracic malignancies, and the use of immunotherapy and targeted therapy. He is dedicated to the treatment of patients with cancer and researching novel treatment approaches to improve outcomes for patients.

Dr. von Itzstein earned his medical degree at Griffith University in Queensland, Australia. He completed both his residency in internal medicine and fellowship in medical oncology at UT Southwestern.

Certified by the American Board of Internal Medicine in medical oncology and internal medicine, he joined the UT Southwestern faculty in 2024.

Dr. von Itzstein is a member of the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer, and he serves as Review Editor for Frontiers in Immunology and Frontiers in Oncology.

He has delivered invited lectures and published peer-reviewed academic articles, reviews, editorials, and case reports related to his areas of expertise. He also has intellectual property related to his studies on genetic predictors of immune-related adverse events. He serves as site principal investigator on several studies.

Personal Note

When he’s not at work, Dr. von Itzstein enjoys traveling with his wife, hiking, and following sports, including tennis, Formula One racing, and rugby.

Education & Training

Medical School - Griffith University, Australia (2014-2017)
Residency - UT Southwestern Medical Center (2018-2020), Internal Medicine
Fellowship - UT Southwestern Medical Center (2020-2024), Medical Oncology

Professional Associations & Affiliations

American Society of Clinical Oncology
International Association for the Study of Lung Cancer

Honors & Awards

Oncology Fellowship Research Award 2021, UT Southwestern Medical Center
Best of the Best Clinical Research Presentation 2021, Clinical Oncology Society of Australia Annual Scientific Meeting
Seldin Award for Outstanding Intern 2019, UT Southwestern Medical Center
University Medal for Academic Excellence 2014-2017, Griffith University, Doctor of Medicine (M.D.)

Books & Publications

Publications
- Acknowledging and addressing real-world challenges to treating immune-related adverse events
  von Itzstein MS, Gerber DE, Bermas BL, Meara A Journal for ImmunoTherapy of Cancer 2024 Jul 12
- Use of artificial intelligence chatbots in clinical management of immune-related adverse events
  Burnette H, Pabani A, Von Itzstein MS, Switzer B, Fan R, Ye F, Puzanov I, Naidoo J, Ascierto PA, Gerber DE, Ernstoff MS, Johnson DB Journal for ImmunoTherapy of Cancer 2024 May 12
- Resistance Mechanisms in ROS1-Positive Lung Cancer: New Insight into a Rare but Clinically Important Entity
  von Itzstein MS, Gerber DE Clinical chemistry 2024 Apr 70 571-573
- Telemedicine and Cancer Clinical Research Opportunities for Transformation
  von Itzstein MS, Gwin ME, Gupta A, Gerber DE Cancer Journal 2024 Jan 30 22-26
- Distinct autoantibody profiles across checkpoint inhibitor types and toxicities
  Mu-Mosley H, von Itzstein MS, Fattah F, Liu J, Zhu C, Xie Y, Wakeland EK, Park JY, Kahl BS, Diefenbach CS, Gerber DE OncoImmunology 2024 13
- Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice
  von Itzstein MS, Yang Y, Wang Y, Hsiehchen D, Sheffield TY, Fattah F, Popat V, Ahmed M, Homsi J, Dowell JE, Rashdan S, Lohrey J, Hammers HJ, Hughes RS, Wang T, Xie Y, Gerber DE Frontiers in immunology 2024 15
- T-cell tolerant fraction as a predictor of immune-related adverse events
  Ostmeyer J, Park JY, Von Itzstein MS, Hsiehchen D, Fattah F, Gwin M, Catalan R, Khan S, Raj P, Wakeland EK, Xie Y, Gerber DE Journal for ImmunoTherapy of Cancer 2023 Aug 11
- Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors
  Mundra V, Yang Y, von Itzstein MS, Fattah F, Gonugunta AS, Hannan R, Pop LM, Zhang Y, Wang Y, Sheffield T, Xie Y, Dowell JE, Homsi J, Rashdan S, Park J, Li Q, Wakeland EK, Gerber DE Translational Oncology 2023 Aug 34
- Antibiotic Prescriptions in Lung Cancer and Melanoma Populations: Differences With Potential Clinical Implications in the Immunotherapy Era
  Gonugunta AS, Von Itzstein MS, Hsiehchen D, Le T, Rashdan S, Yang H, Selby C, Alvarez C, Gerber DE Clinical lung cancer 2023 Jan 24 11-17
- Quantitation of cardiac troponin i in cancer patients treated with immune checkpoint inhibitors: A case-control study
  Ulndreaj A, Brinc D, Altan M, Pons-Belda OD, Fernandez-Uriarte A, Mu-Mosley H, Fattah F, Von Itzstein MS, Soosaipillai A, Kulasingam V, Palaskas NL, Gerber DE, Diamandis EP, Heymach JV, Prassas I Clinical Chemistry and Laboratory Medicine 2023 Jan 61 154-161
- Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report
  Gonugunta AS, von Itzstein MS, Gerber DE Journal of Medical Case Reports 2022 Dec 16
- Correction to: Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors (Cancer Immunology, Immunotherapy, (2022), 71, 9, (2169-2181), 10.1007/s00262-022-03151-2)
  von Itzstein MS, Gonugunta AS, Wang Y, Sheffield T, Lu R, Ali S, Fattah FJ, Xie D, Cai J, Xie Y, Gerber DE Cancer Immunology, Immunotherapy 2022 Sep 71 2183-2184
- Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors
  von Itzstein MS, Gonugunta AS, Wang Y, Sheffield T, Lu R, Ali S, Fattah FJ, Xie D, Cai J, Xie Y, Gerber DE Cancer Immunology, Immunotherapy 2022 Sep 71 2169-2181
- Distinct NSCLC EGFR Variants in a Family With Li-Fraumeni Syndrome: Case Report
  Edmondson S, von Itzstein MS, Reys B, Mayer M, Gagan J, Gerber DE JTO Clinical and Research Reports 2022 Aug 3
- Circulating mitochondrial DNA as a biomarker for lung cancer screening
  von Itzstein MS, Gerber DE, Minna JD Translational Lung Cancer Research 2022 Aug 11 1522-1525
- Systemic and Intracranial Efficacy of Osimertinib in EGFR L747P-Mutant NSCLC: Case Report
  Gerber DE, Mayer M, Gagan J, von Itzstein MS JTO Clinical and Research Reports 2022 Mar 3
- Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy
  von Itzstein MS, Gonugunta AS, Sheffield T, Homsi J, Dowell JE, Koh AY, Raj P, Fattah F, Wang Y, Basava VS, Khan S, Park JY, Popat V, Saltarski JM, Gloria-Mccutchen Y, Hsiehchen D, Ostmeyer J, Xie Y, Li Q, Wakeland EK, Gerber DE Cancers 2022 Mar 14
- Association between immune-related adverse event timing and treatment outcomes
  Hsiehchen D, Naqash AR, Espinoza M, Von Itzstein MS, Cortellini A, Ricciuti B, Owen DH, Laharwal M, Toi Y, Burke M, Xie Y, Gerber DE OncoImmunology 2022 11
- Humoral and cellular correlates of a novel immune-related adverse event and its treatment
  Gonugunta AS, Von Itzstein MS, Mu-Mosley H, Fattah F, Farrar JD, Mobely A, Rashdan S, Lai S, Bhai SF, Bermas BL, Karp D, Li QZ, Wakeland EK, Gerber DE Journal for ImmunoTherapy of Cancer 2021 Dec 9
- Contemporary lung cancer screening and the promise of blood-based biomarkers
  Von Itzstein MS, Gerber DE, Minna JD Cancer research 2021 Jul 81 3441-3443
- Accessing Targeted Therapies: A Potential Roadblock to Implementing Precision Oncology?
  Von Itzstein MS, Smith ML, Railey E, White CB, Dieterich JS, Garrett-Mayer L, Bruinooge SS, Freedman AN, De Moor J, Gray SW, Park JY, Yan J, Hoang AQ, Zhu H, Gerber DE JCO Oncology Practice 2021 Jul 17 E999-E1011
- Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors
  Ahmed M, Von Itzstein MS, Sheffield T, Khan S, Fattah F, Park JY, Popat V, Saltarski JM, Gloria-Mccutchen Y, Hsiehchen D, Ostmeyer J, Khan SA, Sultana N, Xie Y, Li QZ, Wakeland EK, Gerber DE Journal for ImmunoTherapy of Cancer 2021 Jun 9
- Lineage Switching: How lung cancer cells change identity
  Von Itzstein MS, Drapkin BJ, Minna JD eLife 2021 10
- Application of Information Technology to Clinical Trial Evaluation and Enrollment: A Review
  Von Itzstein MS, Hullings M, Mayo HG, Beg MS, Williams EL, Gerber DE JAMA Oncology 2021
- Immunotherapy Use in Patients with Lung Cancer and Comorbidities
  Von Itzstein MS, Gonugunta AS, Mayo HG, Minna JD, Gerber DE Cancer Journal 2020 Nov 26 525-536
- Do mRNA profiles of lung adenocarcinomas provide information that will help individual patients?
  von Itzstein MS, Gerber DE, Minna JD EBioMedicine 2020 Oct 60
- Targeting TAM to Tame Pancreatic Cancer
  von Itzstein MS, Burke MC, Brekken RA, Aguilera TA, Zeh HJ, Beg MS Targeted Oncology 2020 Oct 15 579-588
- Statin Intolerance, Anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A “Two-Hit” Autoimmune Toxicity or Clinical Predisposition?
  von Itzstein MS, Khan S, Popat V, Lu R, Khan SA, Fattah FJ, Park JY, Bermas BL, Karp DR, Ahmed M, Saltarski JM, Gloria-McCutchen Y, Xie Y, Li QZ, Wakeland EK, Gerber DE Oncologist 2020 Aug 25 e1242-e1245
- Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis
  von Itzstein MS, Khan S, Gerber DE Clinical chemistry 2020 Jun 66 779-793
- Closing the gap: Contribution of surgical best practices to outcome differences between high- and low-volume centers for lung cancer resection
  von Itzstein MS, Lu R, Kernstine KH, Halm EA, Wang S, Xie Y, Gerber DE Cancer Medicine 2020 Jun 9 4137-4147
- Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor–Induced Raynaud's-Like Phenomenon
  Khan S, von Itzstein MS, Lu R, Bermas BL, Karp DR, Khan SA, Fattah FJ, Park JY, Saltarski JM, Gloria-McCutchen Y, Xie Y, Li QZ, Wakeland EK, Gerber DE Oncologist 2020 May 25 e753-e757
- Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology
  von Itzstein MS, Railey E, Smith ML, White CB, Sledge GW, Howell JR, Lawton W, Marinucci DM, Unni N, Gerber DE Cancer 2020 Apr 126 1605-1613
- Increased reporting but decreased mortality associated with adverse events in patients undergoing lung cancer surgery: Competing forces in an era of heightened focus on care quality?
  Von Itzstein MS, Gupta A, Kernstine KH, Mara KC, Khanna S, Gerber DE PloS one 2020 Apr 15
- Type and case volume of health care facility influences survival and surgery selection in cases with early-stage non–small cell lung cancer
  Wang S, Lai S, von Itzstein MS, Yang L, Yang DM, Zhan X, Xiao G, Halm EA, Gerber DE, Xie Y Cancer 2019 Dec 125 4252-4259
- Increasing Numbers and Reported Adverse Events in Patients with Lung Cancer Undergoing Inpatient Lung Biopsies: A Population-Based Analysis
  von Itzstein MS, Gupta A, Mara KC, Khanna S, Gerber DE Lung 2019 Oct 197 593-599
- Strategies to maximize influenza vaccine impact in older adults
  Whitaker JA, von Itzstein MS, Poland GA Vaccine 2018 Sep 36 5940-5948
- Severe destructive nasopharyngeal granulomatosis with polyangiitis with superimposed skull base Pseudomonas aeruginosa osteomyelitis
  Von Itzstein MS, Abeykoon JP, Summerfield DD, Whitaker JA BMJ Case Reports 2017 2017

Research

Cancer immunotherapy
Immune-related adverse events
Clinical and translational lung cancer research
Clinical trials

Clinical Focus

Lung Cancer
Immunotherapy
Targeted Therapy
Thoracic Oncology

New Patient Appointment Accepting Virtual Visits or 214-645-4673